By Matt Harrington, BCBA · Behaviorist Book Club · April 2026 · 12 min read

Fad Treatments and Evidence-Based Supervision: Navigating the Crossroads in ABA

Overview & Clinical Significance

Behavior analysts working in interdisciplinary settings routinely encounter requests to implement interventions that lack empirical support or that have been demonstrated to be ineffective or harmful. The professional crossroads created by these encounters — where the obligation to use evidence-based procedures meets the pressure to collaborate, defer to other professionals, or accommodate family preferences — is one of the most clinically and ethically complex situations BCBAs face. This course addresses that crossroads directly.

The prevalence of fad treatments in ABA-adjacent settings is not a fringe concern. Facilitated communication, sensory integration therapy in forms not supported by behavioral evidence, auditory integration training, and numerous supplement-based interventions circulate continuously in the autism treatment landscape, often with persuasive parent testimonials and prominent social media presences that give them disproportionate visibility relative to their evidence base. BCBAs who are unprepared to navigate conversations about these treatments risk either damaging professional relationships through dismissive rejection or compromising their ethical obligations through acquiescence.

Supervision is the professional context in which the next generation of behavior analysts learns how to navigate these crossroads. BCBAs who supervise RBTs, BCBA candidates, and other trainees have a specific responsibility not just to model evidence-based practice but to explicitly teach how to evaluate treatment claims, communicate about fad treatments with families and colleagues, and maintain ethical commitments under institutional or interpersonal pressure. The supervision dimension of this course is therefore both immediately practical — providing guidance for supervisors — and forward-looking, addressing how the field propagates sound professional judgment through training relationships.

Background & Context

The term fad treatment in the autism and ABA context refers to interventions that achieve widespread adoption in clinical or family communities without adequate empirical support. The cycle of fad treatment adoption follows a recognizable pattern: a mechanism or anecdotal outcome is proposed, parent testimonials build enthusiasm, commercial interests amplify the message, and adoption precedes rigorous investigation. Some fad treatments are merely ineffective; others carry genuine harm potential, whether through direct adverse effects, opportunity costs from time and resources spent on ineffective treatment, or the substitution of fad approaches for evidence-based ones.

The historical record of fad treatments in the autism field is extensive. Secretin injections, despite early anecdotal enthusiasm, failed to demonstrate effects in controlled trials. Facilitated communication, perhaps the most extensively studied fad treatment, has been definitively shown to be practitioner-controlled rather than a reflection of the facilitated individual's communication. Gluten-free and casein-free diets have not demonstrated treatment effects in randomized controlled trials for autism outcomes. Yet each of these treatments has maintained a presence in some clinical communities despite the disconfirming evidence.

The interdisciplinary context matters because behavior analysts frequently work alongside professionals from disciplines with different evidentiary standards and different professional training regarding evidence evaluation. Occupational therapists, speech-language pathologists, psychologists, and educators may be unfamiliar with the single-subject experimental methods that constitute behavior analysis's evidentiary foundation, and they may apply evidence standards from their own disciplines that are more permissive of plausibility-based or testimonial evidence. BCBAs who understand both their own evidentiary framework and those of their colleagues are better positioned to engage interdisciplinary conversations about treatment selection constructively.

The supervision literature in behavior analysis has increasingly addressed how to develop clinical judgment and ethical decision-making in trainees, not just technical skills. The competencies required to navigate fad treatment crossroads — evaluating evidence, communicating diplomatically but honestly with families and colleagues, maintaining ethical obligations under pressure — require deliberate cultivation through the supervision relationship.

Clinical Implications

The most direct clinical implication of this course is for treatment planning and team communication. BCBAs who encounter requests to implement or endorse non-evidence-based treatments need a structured decision-making process that is both principled and diplomatically sensitive. The process begins with accurate evaluation of the treatment's evidence base — not dismissal based on unfamiliarity, but systematic review of the experimental literature, including controlled trials and single-subject replications.

When fad treatments are being implemented by families or other providers alongside ABA services, the BCBA's role is not necessarily to eliminate the competing treatment but to ensure that their own services remain evidence-based and that families are adequately informed. Code 2.01 requires behavior analysts to operate within defined areas of competence and to use scientifically supported procedures; it does not require BCBAs to prevent families from accessing other services. However, Code 2.11 requires that informed consent be genuinely informed — families should be aware of the evidence status of all treatments being implemented.

Supervision implications are substantial. RBTs and BCBA candidates who work in settings where fad treatments are present need to understand what behavior analysts can and cannot implement, why the evidentiary standard matters, and how to communicate concerns professionally within a team context. Supervisors who address these topics explicitly in supervision — through case discussion, role-playing difficult conversations, and reviewing the relevant literature together — are equipping trainees with competencies they cannot acquire from technical skill training alone.

The opportunity cost dimension of fad treatments is a clinical concern that BCBAs should articulate when relevant. Time and resources devoted to ineffective interventions are unavailable for evidence-based alternatives. For families of young autistic children, the period during which intensive early intervention produces the most benefit is time-limited. BCBAs who help families understand this time-opportunity relationship — without inducing anxiety or engaging in high-pressure tactics — are serving both the child's clinical interests and the family's genuine informed consent.

Ethical Considerations

Code 2.01 is the central ethical provision for navigating fad treatment crossroads: behavior analysts provide services only within areas of established scientific knowledge and competence, and they use only scientifically supported procedures. This prohibition extends to implementing fad treatments under instruction from a supervisor, employer, or interdisciplinary team member — Code 5.04 requires behavior analysts to follow the most stringent ethics requirements when there is a conflict between ethical codes and institutional requirements.

Code 2.09 requires behavior analysts to use the least restrictive procedures, which has an important but sometimes overlooked dimension in the fad treatment context: least restrictive includes least harmful. When a proposed treatment carries potential for harm — whether physical, psychological, or in terms of opportunity cost — this risk must be weighed against its unsubstantiated claimed benefits. BCBAs are not required to be paralyzed by theoretical harm, but they are required to apply genuine risk-benefit analysis rather than deferring to institutional authority or family preference.

Code 7.01 requires behavior analysts to promote an ethical culture within their organizations. In settings where fad treatments are routinely implemented alongside or instead of evidence-based services, this requirement creates an obligation to raise concerns through appropriate channels — with supervisors, through professional consultation, or through formal ethics processes if necessary. BCBAs cannot simply ignore fad treatment implementation because it does not directly involve their clients or caseload.

Code 3.01 requires behavior analysts to obtain and maintain competence in their areas of practice, which includes maintaining currency with both the evidence base for ABA and the literature on alternative treatments their clients may be receiving. A BCBA who has never reviewed the literature on a specific fad treatment is not positioned to engage it constructively in team discussions or to fulfill their informed consent obligations regarding it.

Assessment & Decision-Making

A structured decision-making framework for fad treatment crossroads involves several sequential steps. First, identify whether the proposed treatment has an empirical literature and evaluate its quality: Are there controlled experimental evaluations? What are the outcome measures? Have findings been replicated? Are there peer-reviewed reviews or meta-analyses? This evaluation should be conducted with the same rigor applied to any clinical decision — which means being prepared to find that treatments initially appearing to lack support have some limited evidence, and that treatments initially appearing established have limited replication.

Second, evaluate the harm potential of the proposed treatment. Some fad treatments are benign in themselves, carrying costs primarily in terms of time and money — this assessment matters for how strongly to advocate against implementation. Others have direct adverse potential, whether physical, psychological, or in terms of creating dependency or delaying access to effective treatment. The strength of the BCBA's professional obligation to address the treatment varies accordingly.

Third, identify the stakeholders whose input is needed for the decision. Is the fad treatment being proposed by a family member? An interdisciplinary team colleague? An employer? The relationship context affects both the communication strategy and the professional obligations involved. A family member proposing a supplement requires a different conversation than an employer directing BCBAs to implement a specific protocol.

Fourth, document the evaluation and the conversations that follow. If a BCBA has expressed professional concerns about a fad treatment — to the family, to an employer, or in a team meeting — documentation of that concern protects both the client and the practitioner. If the treatment is ultimately implemented despite the BCBA's objection, documentation establishes that the practitioner fulfilled their ethical obligation to raise the concern.

What This Means for Your Practice

Navigating fad treatment crossroads is a competency that requires both knowledge and communication skills, and both can be developed deliberately. Three practical action steps follow from this course's content.

First, build and maintain a fad treatment reference resource. Identify the treatments most commonly encountered in your practice setting — sensory-based interventions, dietary approaches, communication devices or methods with contested evidence, any treatment with significant social media presence in the autism community — and conduct a systematic literature review for each. Document your findings and keep the reference current. When these treatments come up in team meetings or family conversations, you are prepared to engage specifically rather than generically.

Second, develop your communication skills for these conversations. The goal is not to win an argument or demonstrate superior knowledge — it is to help families and colleagues understand the evidence base in a way that supports informed decision-making. Practice framing evidence evaluation as a shared process rather than an expert pronouncement. Language such as 'Let's look at what the research shows together' positions you as a collaborative partner rather than a gatekeeper, which produces better outcomes in difficult conversations.

Third, address fad treatment navigation explicitly in supervision with your trainees. Create structured opportunities for trainees to practice evaluating treatment evidence, articulating concerns diplomatically, and maintaining ethical commitments under simulated pressure. Role-playing difficult scenarios — a parent who is emotionally invested in a fad treatment, a supervisor who has adopted a non-evidence-based approach — builds the behavioral fluency that knowledge alone cannot provide.